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Summary
The new paradigm of therapy in rheumatoid arthritis is to
aim toward early and complete remission, using a larger
use of conventional DMARDs and biologic agents. The
present recommendations were established through a con-
sensus to help practitioners in their daily use of those
agents, to reflect the current “best practice” in Switzerland.
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Scope and purpose
Many guidelines for treating rheumatoid arthritis patients
are available, including US and European guidelines. This
document, based on evidence and expert opinion, but
without any formal and systematic process or review of
the literature, presents what is regarded as current practice
by the representatives of the Swiss university hospitals.
Those recommendations are intended as a pragmatic help
for Swiss practitioners to improve standard care in Switzer-
land.
Introduction
Rheumatoid arthritis (RA) is an immune mediated, chronic
and progressive inflammatory joint disease [1] with auto-
immune phenomena such as rheumatoid factor (RF) and
antibodies against citrullinated cyclic peptides (anti-CCP-
antibodies, ACPA), clinically characterised by the sym-
metric involvement of multiple small and large peripheral
joints. RA is the most prevalent inflammatory joint disease
in developed countries, affecting up to 1% of the entire
population. RA may lead to bone erosions and cartilage de-
struction resulting in loss of joint function, severe handicap
and work disability.
There are a few variables which help to predict aggressive
disease course and guide therapy: Presence of RF, CCP
auto-antibodies, high CRP/ESR, early bony erosions and
extra-articular manifestations [2, 3]. Importantly, RA
should never be regarded as trivial, and an early and ad-
apted therapy has to be started as soon as possible. Every
patient presenting with arthritis of more than one joint
and lasting for more than 6 weeks should be evaluated by
a rheumatologist for possible RA. The recent revision of
the ACR/EULAR classification criteria presented at ACR
2009 acknowledges this need [4].
Treatment goals of RA therapy
There is currently no cure for RA, and the vast majority
of patients will have to be treated for the rest of their lives
and with well-defined objectives. With the broad variety
of treatment options, the aim is early and complete re-
mission, which means the absence of swollen and tender
joints, morning stiffness and fatigue, as well as clinical and
laboratory signs of systemic inflammation. Furthermore,
the structural integrity of joints has to be monitored in order
to prevent any (progression of) structural damage, and thus
to prevent handicap and work disability.
The best validated tool for disease activity monitoring is
the disease activity score (DAS). The DAS28 score in-
cludes the number of tender or swollen joints (out of 28
defined joints), acute phase reactants and a general health
evaluation by the patient [5]. Despite limitations, this com-
posite index is the international assessment tool used for
clinical studies, and also to prospectively monitor disease
with the aim to adjust treatment intensity [6–8]. The struc-
tural joint status is monitored by conventional X rays on
a yearly basis. Joint ultrasonography is an ideal bed-side
method to detect early structural changes, and this rapidly
expanding technique will certainly become a standard. The
Swiss Society for Rheumatology (SGR/SSR) provides a
user-friendly web-based tool for longitudinal monitoring
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and documentation of all necessary disease parameters (ht-
tp://scqm.ch). This disease assessment should be com-
pleted on a regular basis, with annual radiographic analyses
and patient-centred assessments of functional status and
quality of life by standardised measures, such as the health
assessment questionnaire of disability (HAQ-DI) or SF-36.
Early DMARD treatment
Patients with diagnosed RA should be started with a
disease-modifying anti-rheumatic drug (DMARD) therapy
as early as possible. Methotrexate (MTX) is the gold stand-
ard drug for mildly to highly active disease activity. The
use of subcutaneous administration, starting with (at least)
10 mg per week and combined with folate substitution
(5–10 mg per week) to minimise side effects is recommen-
ded. MTX dose should be increased by up to 25–30 mg per
week within 2 to 3 months depending on efficacy and tol-
erability.
Monotherapy with other DMARDs such as anti-malarials,
sulfasalazine and leflunomide is recommended for patients
with low disease activity and a lack of bad prognostic
markers. Combinations of MTX with other conventional
DMARD have been tested in several clinical trials, and
were shown to provide some increased efficacy without po-
tentiating toxicity [9, 10]. Systemic or intra-articular gluco-
corticoids may be used to rapidly induce remission but the
daily dose should not exceed 5 mg if given over prolonged
periods (> a few weeks).
Indication for Biologics
Ongoing stringent monitoring of RA disease activity and
progression, as recommended above, allows appropriate
adaptation of DMARD and biologics treatment. The au-
thors of this consensus agree that if low disease activity
or remission (defined for practical purposes as at least
a DAS28 ≤3.2) has not been achieved within 3 months
with the initial conventional DMARD therapy, that the use
of a biologic agent is recommended as the likelihood of
reaching a low disease activity status, after initial failure
of MTX, using subsequent conventional DMARDs is low
[11].
At present, TNF blocking agents are the 1st choice for bio-
logic treatment when conventional DMARD therapy has
failed to induce disease remission. This recommendation is
based on the good clinical experience with anti-TNF-ther-
apy, their demonstrated strong efficacy, their rapid onset of
action and the known benefit–risk profile with over a mil-
lion patients treated up to date and more than a decade of
experience with the use of the three TNF-blocking agents
currently licensed for the Swiss market.
Prior to the initiation of any anti-TNFα therapy, a system-
atic workup has to be performed to exclude the various
contra-indications to such treatment. The current recom-
mendations in regard to this topic released by the Swiss So-
ciety of Rheumatology are available online (www.rheuma-
net.ch/richtlinien).
The choice of the anti-TNF agent used is primarily based
on the individual patient characteristics (such as compli-
ance, preference for long dosing interval with intravenous
administration or preference for self-subcutaneous admin-
istration, venous access) and the availability of the appro-
priate infrastructure for intravenous infusions. The authors
believe there is currently no efficacy or safety data to sug-
gest an overwhelming advantage of one agent over the oth-
ers.
Whenever possible, it is strongly recommended to use any
TNF-blocking agent in combination with MTX, as com-
bination of both agents was superior to monotherapy with
either one of these substances in all clinical trials, in terms
of clinical response, physical function and radiographic
progression [6, 12]. In the case of MTX intolerance, re-
duction of the MTX dose or use of an alternative DMARD
such as leflunomide is recommended. Biologics, such as
monotherapy, should only be considered when traditional
DMARDs are contraindicated. Monotherapies were not
shown to have superior efficacy compared to MTX, except
tocilizumab, a humanised monoclonal antibody against the
interleukin 6-receptor which was more effective in mono-
therapy than MTX alone. However, this study did not in-
clude a combination arm, and for the moment tocilizumab
should also be used whenever possible in association with
MTX [13].
Modification of biologic treatment
The disease course of patients on an anti-TNF therapy is
not linear. Thus, disease activity has to be tightly monitored
with treatment modification in case of a lack of/or insuffi-
cient efficacy, or a secondary loss of response, while some
treatment de-escalations may be considered in the case of
persisting remission.
Insufficient response or secondary loss of response:
If remission is not reached or is lost after an initial favour-
able response, modification or intensification of therapy is
mandatory. In the setting of a significant clinical response,
such as a good EULAR response, but in the absence of
remission, treatment optimisation with a dose increase of
the conventional DMARD and/or the addition of another
DMARD, as well as short-term gluco-corticoids are reas-
onable options for the authors, even if no formal trials sup-
port these suggestions.
In the absence of a response, or if a tentative optimisation
fails, the anti-TNF agent should be stopped and an alternat-
ive biologic agent should be used; either an alternative anti-
TNF agent or a biologic agent with a different mode of ac-
tion such as rituximab, abatacept or tocilizumab. Efficacy,
in this difficult-to-treat TNF-resistant population, has been
demonstrated for all of these agents in randomised con-
trolled trials [14–16]. Whether changing to a second TNF
blocker or to a biologic with a different mechanism of ac-
tion is the better option has not been evaluated in head-to-
head trials [17–24]. The preference for currently available
treatment strategies in this setting still varies from centre to
centre.
Remission
In case of remission, even if the optimal therapeutic
strategy remains unknown, all centres agree that gluco-cor-
ticoids should be tapered first and discontinued whenever
possible. The authors agree that the dosage of either the
biologic or the conventional DMARD should not be mod-
ified for at least 6 months of persisting remission. There-
after, treatment intervals of biologics are prolonged and
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biologics are finally stopped with ongoing DMARD ther-
apy.
Drug-free remission:
The ultimate goal of treatment would be an ongoing drug-
free remission. Based on the results of the BEst study, it
appears possible to discontinue anti-TNF therapy as well
as concomitant DMARD in a small percentage of patients
[25]. However, these patients were treated very early and
very aggressively (combination of infliximab and MTX).
The data led to the hypothesis that there exists a “window
of opportunity” (i.e., an, as yet, undefined time slot in early
RA) when it is possible to eradicate all disease processes
and achieve a “re-set” of inflammatory and autoimmune
phenomena. In such cases, it remains even more crucial to
tightly monitor the patients for any signs of reactivation or
structural damage progression, with prompt resumption of
therapy if needed.
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